Drug
Icp 248
Icp 248: highest development phase Phase 3, developed by InnoCare Pharma. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| ICP-248 NCT07784101 | Phase 3 | Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
| ICP-248 NCT06378138 | Phase 2/3 | Hematologic Malignancies |
| ICP-248 NCT07082686 | Phase 2 | Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
| ICP-248 NCT06351527 | Phase 1 | Mature B-cell Malignancies |
Latest
No recent events.
Follow Icp 248 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.